Dr. Bedros Taslakian

Research Leadership and Clinical Trials As Vice Chair of Research, Dr. Taslakian stands at the forefront of advancing his field. His research focuses on interventional oncology, minimally invasive musculoskeletal interventions, venous thromboembolism, portal hypertension, and other image-guided therapies. Key Research Highlights: National Clinical Trials: Dr. Taslakian served as the site Principal Investigator (PI) for the landmark, NIH-funded PE-TRACT trial, a major randomized study on catheter-directed therapy for pulmonary embolism. Dr. Taslakian has served as a co-investigator on multiple other NIH-, society-, and industry- funded trials. Genicular Artery Embolization (GAE): Dr. Taslakian leads investigator-initiated studies and pioneered the early clinical development of GAE for knee osteoarthritis, publishing a foundational and award-winning prospective study in the Journal of Vascular and Interventional Radiology (JVIR). Prolific Speaker and Author: He has authored over 50 peer-reviewed publications and frequently serves as an invited speaker, moderator, and panelist at prestigious international and national conferences, including the Society of Interventional Radiology (SIR), the Global Embolization Symposium & Technologies (GEST), and the Vascular Embolotherapy and Nerve interventions Targeting Inflammation and pain (VENTI) Research interests: Dr. Taslakian's research is dedicated to advancing minimally invasive, image-guided therapies, focusing on high-impact clinical areas to improve patient outcomes. His primary research interests include pioneering innovative musculoskeletal interventions, such as Genicular Artery Embolization (GAE) for knee osteoarthritis and transcatheter embolization for chronic tendinopathies. He is a recognized leader in venous thromboembolism (VTE) research, having served as a site principal investigator for major national studies like the NIH-funded PE-TRACT trial, evaluating catheter-directed therapy for pulmonary embolism. Additionally, his scholarly work explores novel treatments in portal hypertension and liver-directed therapies, as well as the rapidly evolving field of interventional oncology. Through both investigator-initiated and multicenter NIH-funded trials, Dr. Taslakian is committed to developing evidence-based strategies that transition cutting-edge technology into standard, effective clinical practice.

Dr. Taslakian is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Sternal Cleft, Osteoarthritis, Saddle Pulmonary Embolism, Liver Embolization, and Thrombectomy.

He is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 2 clinical trials. Dr. Taslakian is currently accepting new patients.